A novel technique for detecting antibiotic-resistant typhoid from rapid diagnostic tests. by Nic Fhogartaigh, Caoimhe et al.
LSHTM Research Online
Fhogartaigh, Caoimhe Nic; Dance, David AB; Davong, Viengmon; Tann, Pisey; Phetsouvanh, Rat-
tanaphone; Turner, Paul; Dittrich, Sabine; Newton, Paul N; (2015) A Novel Technique for Detecting
Antibiotic-Resistant Typhoid from Rapid Diagnostic Tests. JOURNAL OF CLINICAL MICROBI-
OLOGY, 53 (5). pp. 1758-1760. ISSN 0095-1137 DOI: https://doi.org/10.1128/JCM.00531-15
Downloaded from: http://researchonline.lshtm.ac.uk/4652794/
DOI: https://doi.org/10.1128/JCM.00531-15
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
A Novel Technique for Detecting Antibiotic-Resistant Typhoid from
Rapid Diagnostic Tests
Caoimhe Nic Fhogartaigh,a,b David A. B. Dance,a,b,c Viengmon Davong,a Pisey Tann,d Rattanaphone Phetsouvanh,a Paul Turner,c,d
Sabine Dittrich,a,c Paul N. Newtona,c
Lao—Oxford—Mahosot Hospital—Wellcome Trust Research Unit, Microbiology Laboratory, Vientiane, Lao PDRa; Public Health England, London, Englandb; Centre for
Tropical Medicine and Global Health, Nuffield Department of Medicine, Old Road Campus, University of Oxford, Oxford, Englandc; Cambodia—Oxford Medical Research
Unit, Angkor Hospital for Children, Siem Reap, Cambodiad
Fluoroquinolone-resistant typhoid is increasing. An antigen-detecting rapid diagnotic test (RDT) can rapidly diagnose typhoid
from blood cultures. A simple, inexpensive molecular technique performed with DNA from positive RDTs accurately identified
gyrAmutations consistent with phenotypic susceptibility testing results. Field diagnosis combined with centralized molecular
resistance testing could improve typhoid management and surveillance in low-resource settings.
Antimicrobial resistance is a global problem of increasing con-cern. Over the past decade, strains of Salmonella enterica
subsp. enterica serovar Typhi with ciprofloxacin MICs in the “in-
termediate” range have emerged and have been associated with
adverse clinical outcomes and increased mortality (1, 2), leading
to a lowering of ciprofloxacin breakpoints for S. Typhi (3, 4).
Fluoroquinolone-resistant (FQR) S. Typhi is reported in 40 to
60% of typhoid cases (5, 6), with considerable geographical vari-
ation. Prevalence has reached 97% in southern Vietnam (5) and
90% in Cambodia (7), which is of great concern, as fluoroquino-
lones have become the mainstay of treatment for uncomplicated
infection in areas where typhoid is endemic, except where the
prevalence of resistance is known to be high, due to their ease of
oral administration and low costs. Over 90% of FQR S. Typhi
isolates are associated with point mutations in the gyrA gene, and
the most common mutation is Ser83¡ Phe (5).
Optimal detection of fluoroquinolone resistance by conven-
tional techniques requires sophisticated laboratories that are able
to use expensive consumables, have well-trained staff, and utilize
quality assurance measures (8). With such capacities largely lack-
ing in low- or middle-income countries, innovative approaches
are needed.We demonstrated the utility of an antigen-detecting S.
Typhi rapid diagnostic test (RDT) performed with blood culture
fluid containingGram-negative rods (GNRs) in typhoid diagnosis
(9). As DNA extracts from RDTs and dried blood spots have been
used for molecular surveillance of malaria and HIV drug resis-
tance (10–12), we hypothesized that mutations in the gyrA gene
could be detected from S. Typhi-positive RDTs, facilitating opti-
mized treatment and public health interventions in remote areas.
A pilot study was conducted to optimize methodologies, followed
by a prospective, multicenter, hospital-based study that evaluated
the sensitivity of gyrAmutation detection via RDTs and compared
these results to those obtainedwith standard susceptibility testing.
Pilot study. Negative blood culture bottles (7 days) were
seeded with150 cells of S. Typhi NCTC 8385, reincubated, and
inspected daily. A Gram stain was performed on turbid bottles to
confirm the presence of GNRs. Ten bottles containing GNRs were
used to inoculate 10 One-Step Salmonella Typhi antigen rapid
detection kits (Standard Diagnostics, South Korea), which were
used to optimize DNA extraction protocols (Fig. 1). Detection of
the gyrA gene and its mutations was performed using previously
described primers under slightly modified PCR conditions, fol-
lowed by restriction fragment length polymorphism (RFLP) anal-
ysis (13). DNA from each section and extraction method under-
went PCR as neat and diluted (1:10, 1:100, and 1:1,000) samples,
plus 40g of bovine serum albumin (BSA;NewEngland BioLabs)
per reaction mixture to overcome inhibitors (14, 15). Subse-
quently, the intensities of bands on an agarose gel were compared,
and the bands giving the greatest intensities were chosen as indi-
cators for the optimal processing method. Wild-type S. Typhi
NCTC 8385 and well-characterized strains with known gyrAmu-
tations, provided byOxfordUniversityClinical ResearchUnit,Ho
Chi Minh City, Vietnam (16), were used as controls.
The optimal protocol for DNA extraction was found to be the
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FIG1 A SalmonellaTyphi rapid diagnostic test. Each RDT strip is divided into
five sections: sample (S), conjugate (C), proximal result (PR), distal result
(DR), and absorption pads (A), which were cut into 2-mm strips to compare
DNA extraction by elution or a column-based method.
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elution method (12), which consistently yielded more DNA than
the column-based commercial kit (Qiagen, Germany). Sample or
conjugate sections at the final dilution of 1:100 yielded similarly
large amounts of DNA (Fig. 1).
Prospective evaluations. For the prospective evaluations,
blood cultures taken with written and/or verbal informed consent
from patients of all ages at Mahosot Hospital, Vientiane, Laos
(May to October 2013) and children 15 years old at Angkor
Hospital for Children (AHC), Siem Reap, Cambodia (June to Oc-
tober 2013) were included. Ethical clearance was granted by the
Oxford Tropical Research Ethics Committee, University of Ox-
ford, United Kingdom, and local ethics committees.
Positive blood culture fluid containing GNRs was used to per-
form the S. Typhi RDT, and positive RDTs were individually
stored in ziplock bags at 4°C until extraction and gyrA PCR-RFLP.
The positive RDT samples from Cambodia were transported to
the Mahosot laboratory at ambient temperature (maximum 36 h
of travel) (17). Antimicrobial susceptibility testing of confirmed
isolates was performed according to published guidelines, includ-
ing disk-diffusion tests (Oxoid, United Kingdom) for ciprofloxa-
cin (5 g) and nalidixic acid (30 g) and MIC testing via Etest
(bioMérieux, France) for ciprofloxacin (18, 19). RDTs were per-
formed on GNR-containing blood cultures from 172 patients
(Laos, n  136; Cambodia, n  36). RDTs were positive for 38
patients (Laos, 28/136 [20.6%]; Cambodia, 10/36 [27.8%]), in-
cluding 31 S. Typhi and 7 non-S. Typhi group D salmonellae.
Available RDT samples (from total RDTs, 31/38 [81.6%]; S. Ty-
phi, 25/31 [80.6%]; group D salmonellae, 6/7 [85.7%]) were
tested under the optimized gyrA detection protocol. The median
time from RDT to extraction was 42 days (range, 8 to 134 days).
All S. Typhi gyrA results showed 100%agreementwith phenotypic
susceptibilities, including 7 FQR cases: 1/19 (5.3%) fromLaos had
a single mutation at codon 83; 4/6 (66.7%) from Cambodia had a
single mutation at codon 83, and 2/6 (33.3%) had double muta-
tions at codons 83 and 87 (Table 1).
The method, albeit with a small sample size, was therefore
100% sensitive and 100% specific in detecting gyrA mutations
from RDT-derived DNA to predict FQR S. Typhi.
Limitations of the study are that the RDT also detects other
group D salmonellae that share the O9 antigen, and the current
PCR-RFLP only detects gyrAmutations. An additional molecular
test to confirm S. Typhi (20) could be incorporated into a multi-
plex or nested PCR, which could be further developed to include
primers for other resistance genes, should these become more
prevalent, with the option of subsequent sequencing to provide
more-detailed molecular epidemiology data on resistance and
phylogeny.
After RDTs are conducted on S. Typhi isolates in the field, the
small RDT package can be conveniently transported to a central
reference laboratory, eliminating the risk of injuries from sharp
medical instruments (needles) and blood-borne infections from
transport of blood culture bottles. Although RDTs contain fewer
viable organisms than bacterial colonies (21), inactivation tech-
niques, used successfully for other bacterial pathogens (22), could
further decrease risks and make our approach more applicable to
field conditions. As standard susceptibility testing of blood culture
isolates takes two additional days, if RDTs are shipped speedily,
the PCR-RFLP can provide accelerated results to guide patient
management within the same day. This could be particularly use-
ful during outbreak investigations. However, as rapid transport
depends on the local infrastructure, larger feasibility studies are
needed to investigate the real-life impact of molecular resistance
testing on patient or outbreak management. Even if patient man-
agement cannot be directly influenced due to transport con-
straints, batched results will provide valuable data for FQR sur-
veillance to inform public health guidelines and treatment
policies.
In conclusion, with the increasing global frequency of drug
resistance, use of molecular markers from RDTs represents an
innovative, accurate, and potentially cost-effective method for
both individual patient diagnosis and public health surveillance in
countries without accessible clinical microbiology laboratories.
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TABLE 1 Results of PCR and RFLP for gyrA mutations in S. Typhi and
corresponding ciprofloxacin MIC resultsa
Lab. ID no. Country
CIP MIC
(g/ml)
Interpretation
(S/I/R)
PCR-RFLP result
(WT or mutated
codon[s])
2956 Laos 0.012 S WT
2957 Laos 0.008 S WT
2965 Laos 0.016 S WT
3009 Laos 0.016 S WT
27416 Laos 0.023 S WT
3624 Laos 0.25 I 83
3770 Laos 0.016 S WT
2986 Laos 0.016 S WT
27545 Laos 0.016 S WT
3823 Laos 0.023 S WT
27986 Laos 0.012 S WT
27987 Laos 0.012 S WT
28247 Laos 0.012 S WT
28257 Laos 0.012 S WT
28317 Laos 0.016 S WT
28373 Laos 0.008 S WT
28403 Laos 0.032 S WT
28412 Laos 0.008 S WT
3862 Laos 0.023 S WT
3286 Cambodia 0.5 I 83, 87
3472 Cambodia 0.5 I 83
3473 Cambodia 0.5 I 83
3489 Cambodia 0.5 I 83, 87
3543 Cambodia 0.5 I 83
4402 Cambodia 0.25 I 83
a Isolates were identified by using the API 20E test (Laos) or an in-house biochemical
test set (Cambodia) and Salmonella Omni-O, O9, Vi, and Hd antisera (Pro-lab
Diagnostics, United Kingdom) at both sites. Every PCR-RFLP investigation included
the following controls to guide interpretation. S83F (gyrA codon 83): nalidixic acid
(NA) MIC of 256 g/ml, ofloxacin (OFX) MIC of 0.38 g/ml, ciprofloxacin (CIP) MIC
of 0.125 g/ml. D87A (gyrA codon 87): NA MIC of 48 g/ml, OFX MIC of 0.19 g/ml,
CIP MIC of 0.094 g/ml. S80I (gyrA codons 83 and 87; parC codon 80): NA MIC of
256 g/ml, OFX MIC of 16 g/ml, CIP MIC of 8 g/ml. S, sensitive; I, intermediate; R,
resistant; WT, wild type.
Detection of gyrA Resistance Markers via Rapid Tests
May 2015 Volume 53 Number 5 jcm.asm.org 1759Journal of Clinical Microbiology
REFERENCES
1. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S,
Segler SD, Megginson M, Luedeman LJ, Shiferaw B, Hanna SS, Joyce
KW, Mintz ED, Angulo FJ, Emerging Infections Program FoodNet,
NARMS Working Groups. 2008. Clinical response and outcome of in-
fection with Salmonella enterica serotype Typhi with decreased suscepti-
bility to fluoroquinolones: a United States FoodNet multicenter retro-
spective cohort study. Antimicrob Agents Chemother 52:1278–1284.
http://dx.doi.org/10.1128/AAC.01509-07.
2. Parry CM, Vinh H, Chinh NT, Wain J, Campbell JI, Hien TT, Farrar JJ,
Baker S. 2011. The influence of reduced susceptibility to fluoroquinolones in
Salmonella enterica serovar Typhi on the clinical response to ofloxacin
therapy. PLoS Negl Trop Dis 5:e1163. http://dx.doi.org/10.1371/journal
.pntd.0001163.
3. Clinical and Laboratory Standards Institute. 2013. Performance stan-
dards for antimicrobial disk susceptibility tests; 23rd information supple-
ment, CLSI document M100-S23. Clinical and Laboratory Standards In-
stitute, Wayne, PA.
4. Humphries RM, Fang FC, Aarestrup FM, Hindler JA. 2012. In vitro
susceptibility testing of fluoroquinolone activity against Salmonella: re-
cent changes to CLSI standards. Clin Infect Dis 55:1107–1113. http://dx
.doi.org/10.1093/cid/cis600.
5. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga
TT, Van Vinh Chau N, Tuan PQ, Page AL, Ochiai RL, Schultsz C, Wain
J, Bhutta ZA, Parry CM, Bhattacharya SK, Dutta S, Agtini M, Dong B,
Honghui Y, Anh DD, Canh do G, Naheed A, Albert MJ, Phetsouvanh R,
Newton PN, Basnyat B, Arjyal A, La TT, Rang NN, Phuong le T, Van Be
Bay P, von Seidlein L, Dougan G, Clemens JD, Vinh H, Hien TT, Chinh
NT, Acosta CJ, Farrar J, Dolecek C. 2007. Antimicrobial drug resistance of
Salmonella enterica serovar Typhi in Asia and molecular mechanism of
reduced susceptibility to the fluoroquinolones. Antimicrob Agents Che-
mother 51:4315–4323. http://dx.doi.org/10.1128/AAC.00294-07.
6. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacha-
rya SK, Agtini MD, Bhutta ZA, Canh do G, Ali M, Shin S, Wain J, Page
AL, Albert MJ, Farrar J, Abu-Elyazeed R, Pang T, Galindo CM, von
Seidlein L, Clemens JD, Domi Typhoid Study Group. 2008. A study of
typhoid fever in five Asian countries: disease burden and implications for
controls. BullWorldHealthOrgan 86:260–268. http://dx.doi.org/10.2471
/BLT.06.039818.
7. Emary K, Moore CE, Chanpheaktra N, An KP, Chheng K, Sona S, Duy
PT, Nga TV, Wuthiekanun V, Amornchai P, Kumar V, Wijedoru L,
Stoesser NE, Carter MJ, Baker S, Day NP, Parry CM. 2012. Enteric fever
in Cambodian children is dominated by multidrug-resistant H58 Salmo-
nella enterica serovar Typhi with intermediate susceptibility to ciprofloxa-
cin. Trans R Soc Trop Med Hyg 106:718–724. http://dx.doi.org/10.1016
/j.trstmh.2012.08.007.
8. Peacock SJ, Newton PN. 2008. Public health impact of establishing the
cause of bacterial infections in rural Asia. Trans R Soc Trop Med Hyg
102:5–6. http://dx.doi.org/10.1016/j.trstmh.2007.06.004.
9. Castonguay-Vanier J, Davong V, Bouthasavong L, Sengdetka D, Sim-
malavong M, Seupsavith A, Dance DA, Baker S, Le Thi Phuong T,
Vongsouvath M, Newton PN. 2013. Evaluation of a simple blood culture
amplification and antigen detection method for diagnosis of Salmonella
enterica serovar Typhi bacteremia. J ClinMicrobiol 51:142–148. http://dx
.doi.org/10.1128/JCM.02360-12.
10. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. 2010.
Dried blood spots for HIV-1 drug resistance and viral load testing: a re-
view of current knowledge and WHO efforts for global HIV drug resis-
tance surveillance. AIDS Rev 12:195–208. http://www.aidsreviews.com
/files/2010_12_4_195-208.pdf.
11. Cnops L, Boderie M, Gillet P, Van Esbroeck M, Jacobs J. 2011. Rapid
diagnostic tests as a source of DNA for Plasmodium species-specific real-
time PCR. Malar J 10:67. http://dx.doi.org/10.1186/1475-2875-10-67.
12. Morris U, Aydin-Schmidt B, Shakely D, Martensson A, Jornhagen L, Ali
AS, Msellem MI, Petzold M, Gil JP, Ferreira PE, Bjorkman A. 2013.
Rapid diagnostic tests for molecular surveillance of Plasmodium falcipa-
rummalaria: assessment of DNA extraction methods and field applicabil-
ity. Malar J 12:106. http://dx.doi.org/10.1186/1475-2875-12-106.
13. Giraud E, Brisabois A, Martel JL, Chaslus-Dancla E. 1999. Comparative
studies of mutations in animal isolates and experimental in vitro- and in
vivo-selected mutants of Salmonella spp. suggest a counterselection of
highly fluoroquinolone-resistant strains in the field. Antimicrob Agents
Chemother 43:2131–2137.
14. Al-Soud WA, Radstrom P. 2001. Purification and characterization of
PCR-inhibitory components in blood cells. J Clin Microbiol 39:485–493.
http://dx.doi.org/10.1128/JCM.39.2.485-493.2001.
15. Fredricks DN, Relman DA. 1998. Improved amplification of microbial
DNA from blood cultures by removal of the PCR inhibitor sodium polya-
netholesulfonate. J Clin Microbiol 36:2810–2816.
16. Baker S, Duy PT, Nga TV, Dung TT, Phat VV, Chau TT, Turner AK,
Farrar J, Boni MF. 2013. Fitness benefits in fluoroquinolone-resistant
Salmonella Typhi in the absence of antimicrobial pressure. eLife 2:e01229.
http://dx.doi.org/10.7554/eLife.01229.
17. Blacksell SD, Khounsy S, Phetsouvanh R, Newton PN. 2006. A simple
and inexpensive container for the transport of biological specimens in
limited resource situations. Trans R Soc Trop Med Hyg 100:1084–1086.
http://dx.doi.org/10.1016/j.trstmh.2006.03.005.
18. Clinical and Laboratory Standards Institute. 2012. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically; ap-
proved standard, 9th ed. CLSI document M07-A9. Clinical and Labora-
tory Standards Institute, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2013. Performance stan-
dards for antimicrobial susceptibility testing; 23rd informational supple-
ment. CLSI document M100-S23. Clinical and Laboratory Standards In-
stitute, Wayne, PA.
20. Zhou L, Pollard AJ. 2010. A fast and highly sensitive blood culture PCR
method for clinical detectionofSalmonella enterica serovar Typhi. AnnClin
Microbiol Antimicrob 9:14. http://dx.doi.org/10.1186/1476-0711-9-14.
21. Smit PW, Elliott I, Peeling RW, Mabey D, Newton PN. 2014. An
overview of the clinical use of filter paper in the diagnosis of tropical
diseases. Am J Trop Med Hyg 90:195–210. http://dx.doi.org/10.4269
/ajtmh.13-0463.
22. Burger M, Raskin S, Brockelt SR, Amthor B, Geiss HK, Haas WH. 1998.
DNA fingerprinting of Mycobacterium tuberculosis complex culture iso-
lates collected in Brazil and spotted onto filter paper. J Clin Microbiol
36:573–576.
Nic Fhogartaigh et al.
1760 jcm.asm.org May 2015 Volume 53 Number 5Journal of Clinical Microbiology
